Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

About this update from Mobia Medical, Inc.

Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years AUSTIN, Texas, July 14, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the publication of two-year follow-up data from the VNS-REHAB study in  Neurology ® , the official peer-reviewed journal of the American Academy of Neurology. The findings demonstrate that statistically significant and clinically meaningful improvements in upper-limb motor impairment and function, ability to perform activities of daily living, and quality of life were sustained for at least two years following completion of in-clinic Vivistim® Paired VNS™ Therapy. With its publication, this data now represents some of the most comprehensive longitudinal evidence to date for any intervention approved for chronic ischemic stroke recovery. The two-year follow-up data , published in Neurology, reports outcomes from 49 participants in the VNS-REHAB pivotal trial, demonstrating a high responder rate and substantial improvements in impairment and function including: Importantly, these upper-limb motor improvements also translated into impactful real-world changes in the daily lives of stroke survivors. Participants demonstrated statistically significant and clinically meaningful improvements across multiple patient-reported measures of activity, participation, and quality of life, including:

View stock analysis, news, and events for Mobia Medical, Inc.